echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Anti-tumor activity and related biomarkers of Wee1 inhibitor Adavosertib (AZD1775) in patients with advanced solid tumors

    Clin Cancer Res: Anti-tumor activity and related biomarkers of Wee1 inhibitor Adavosertib (AZD1775) in patients with advanced solid tumors

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cell cycle checkpoints give cells time to repair DNA damage and chromatin damage before cell division, thereby avoiding replication disasters


    Wee1 kinase inhibitor Adavosertib can stop cell cycle arrest and cause cell death


    The study adopted a 3+3 dose escalation design, 21 days as a course of treatment, and Adavosertib was taken once a day on Days 1-5 and Days 8-12


    Adavosertib plasma concentration changes

    Adavosertib plasma concentration changes

    A total of 42 patients were recruited


    The dose of Adavosertib is 300 mg once daily

    Treatment remission

    Treatment remission

    Six patients (14%) achieved a confirmed partial remission: 4 cases of ovarian cancer and 2 cases of endometrial cancer


    Six patients (14%) achieved a confirmed partial remission: 4 cases of ovarian cancer and 2 cases of endometrial cancer


    Adverse reactions

    Adverse reactions

    The most common adverse reactions are gastrointestinal and blood; dose-limiting toxicity is grade 4 hematological toxicity and grade 3 fatigue


    In summary, the study evaluated the efficacy of Adavosertib RPh2D once a day for advanced solid tumors.


    Original source:

    Original source:

    Naoko Takebe, et al.


    Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.